International Journal of Medical Science in Clinical Research and Review
Online ISSN: 2581-8945
Available Online at http://www.ijmscrr.in Volume 7|Issue 03 (May-June) |2024 Page: 570-581
Review Paper

Comparative Efficacy of Radiological Modalities in the Diagnosis and Staging of Breast Cancer: A Comprehensive Review

Authors:
Deepensha Patel [1], Amit Pratap Singh Chouhan [1*], Ankush Verma [1], Anamika Tiwari [1], Sapna Yadav[1], Vandana Singh [2]
[1]*Department of Radiology, Sharda School of Allied Health Sciences, Sharda University.*
[2]*Department of Microbiology, Sharda school of Allied Health Sciences, Sharda University.*
***Corresponding Author**:
Amit Pratap Singh Chouhan

Article Received: 19-April-2024, Revised: 09-May-2024, Accepted: 29-May-2024

ABSTRACT:
The need for multi-level disease care is highlighted by the alarming increase in breast cancer cases. Strict cancer screening programmes or a cancer registry should be the first step in effective management, which should then be followed by effective diagnostic and therapeutic strategies. Breast cancer is extremely variable both in terms of morphology and at the molecular level, necessitating several therapy modalities depending on the molecular subtype. Clinical prognoses for breast cancer patients vary depending on their subtype. The heterogeneity of breast cancer draws attention to the improved that will help with early detection and improved lives of human being. In developed countries, breast cancer affects 12% of women between the ages of 20 and 40, in this population. The risk of long-term side effects from treatment and their impact on quality of life have become increasingly crucial as breast cancer survival rates have significantly increased. Young women make up a small part of breast cancer patients, but they frequently face distinct issues than older women, such as fears about pregnancy, fertility, and contraception. Furthermore, they are worry about the potential negative effects of treatment, the possibility of a recurrence, or the development of a new primary. Additionally, many patients will develop treatment-related side effects, which can be challenging to manage. Emerging disciplines like biopsy and intelligence will help to better understand the complexities of the tumour disease and would help to select the regimen that supports breast disease. For the curing of breast cancer, a numerous of therapies are including surgery, radiation, chemotherapy, endotherapy, and immunotherapy.

Keywords: Chemotherapy, Surgery, Endotherapy, Clinical prognoses, Immunotherapy.

INTRODUCTION:

Tumour is a very dangerous condition for women due to its high rates of morbidity and death. The six-year recovery rate for aggressive breast cancer is less than 50, even with preventative therapy. There were 2.4 million new instances of breast cancer globally (12.7%), according to data from 186 nations recently released by the fatality rate was 7.9%. Breast cancer is more common (671/200 000 cases compared to 96/20 000 in low-income countries), underscoring the connection to industrialization. Uncontrolled growth of breast cell populations results in the development of breast cancer. Breast cancer can manifest itself in several ways. The process by which breast cells develop into tumours determines the kind of breast cancer. There are several locations on the breast where breast cancer can manifest. Lobules, ducts, and connective tissue make up the breast's three primary structural components. These lobules contain the milk-producing glands. The ducts that carry lactate are cracks. When healthy cells in the breast begin to change and grow out of control, a tumour, which is a mass or sheet of cells, begins to form. Cancerous and benign tumours are also conceivable. The ability of a cancerous tumour to develop and spread to different bodily sites is referred to be malignant. The most advanced stage of breast cancer is stage IV, or metastatic. The presence of neighboring lymph nodes, however, does not always indicate stage IV breast cancer. Breast cancer may return locally, i.e., in the same breast or nearby lymph nodes, after initial therapy. A distant or metastatic recurrence is when the cancer returns in a different part of the body.

Breast Cancer:

Breast cancer is one form of cancer that can appear in the breast. It may begin in either the left or right breast. Cancer develops when cells start to grow uncontrollably. Breast cancer mostly affects women, while it can also occur in men. It is crucial to note that

the majority of breast lumps are benign and not malignant (cancer). Breast tumours that are not malignant are abnormal growths that do not protrude from the breast. A woman's chance of acquiring breast cancer might increase even if the majority of benign breast lumps are not life-threatening.

Breast Cancer Starts:

There are several locations in the breast where breast cancer can manifest. Over the upper ribs and chest muscles, the breast is an organ. Fat, ducts, and glands make up the majority of the structures in the left and right breasts. For the aim of feeding babies and infants, female breasts produce and release milk. A breast's size is influenced by the amount of fatty tissue present.

On rare occasions, breast tumours spread to areas outside the breast. These malignancies, which are not commonly thought of as breast cancers, go by the designation's sarcomas and lymphomas. Breast cancer is the most common malignancy among adolescents and young adults (AYA) between the ages of 15 and 39, accounting for 5.6% of all cases of invasive breast cancer in women. AYAs are more likely than older women to contain genes associated with unsatisfactory outcomes, distant metastatic illness at diagnosis, bigger breast tumours, undesirable biological characteristics, and family history of cancer. For younger and older women, different endocrine treatments and types of chemotherapy are advised. AYAs need multidisciplinary integrated care, proactive sexual and mental health management both before and after cancer treatment, and treatment plans that reduce side effects including osteoporosis and early menopause.

How Breast Cancer Spreads:

Little glands, lymph nodes are the size of beans. Immune system cells, debris, and tissue-production byproducts are all present in the clear lymph fluid that fills the lymph veins.



Fig. Showing the anatomy of normal breast.

Types of Breast Cancer:

Breast cancer comes in a variety of forms. The kind depends on which particular breast cells are impacted. The majority of breast cancer instances are carcinomas. The majority of cases of breast cancer are adenocarcinomas, which include invasive carcinoma and ductal carcinoma in situ, which develop from gland cells in the lobules (milk-producing glands) or milk ducts. Angiosarcoma and sarcoma are two other cancer forms that can develop in the breast but are not often referred to as breast cancer despite beginning in distinct breast cells. Several different types of proteins or genes that each tumour may produce are used to further categorise breast cancers. In the lab, the cancer cells are also carefully examined to determine the tumor's grade. The stage of the malignancy and prospective therapies can be determined using the particular proteins that have been identified and the cancer grade.

What Causes Breast Cancer:

It is well recognized that mutated or altered genes can cause aberrant breast cells to develop into cancer. However, it is estimated that only 20% of tumour caused by bacteria or some stimuli.

How Gene Changes Can Lead to Breast Cancer:

Our cells' operations are governed by our genes. Our parents both contributed DNA, which gives them structure. Our DNA affects both our appearance and susceptibility. Proto-oncogenes, which are found in normal cells, assist in regulating how much a cell develops, divides to produce new cells, or keeps itself alive. A proto-oncogene may develop into an oncogene as a result of certain mutations. These mutant oncogenes are capable of causing cellular malignant, are also present in normal cells. A cell may develop cancer if a gene that normally suppresses tumours is altered.

Inherited Gene Changes:

You can inherit or get certain gene modifications (mutations) by way of your parents. This suggests that at birth, every cell in your body contains the mutations. Inherited gene abnormalities, which are also linked to many cancers that occur in particular

families, can greatly raise the risk of developing various cancer. When these genes are altered, they stop regulating aberrant cell development, which increases the chance of getting cancer. One of these genes could alter from parent to kid due to genetic inheritance. Then, by paying closer attention to their breasts and adhering to the proper screening recommendations to help find cancer at an earlier, more treatable stage, these women can take steps to lower their risk of developing breast cancer. Because these mutations are frequently associated with other cancers (including breast cancer), women who carry them should consider early screening and prophylactic measures for other cancers. The implicated genes may have an impact on metabolism, hormone levels, or other elements that influence the risk of breast cancer. The risk of breast cancer that runs in families may also be greatly affected by these genes.

Acquired Gene Changes:

Breast cancer-related gene mutations are often acquired. This shows that the alteration in breast cells develops during the course of a person's present at birth. Over time, acquired DNA changes only occur in breast cancer cells. Radiation or other carcinogens may cause these acquired mutations in tumour suppressor and/or oncogene genes. But some gene changes might just be accidental occurrences that once in a while happen inside a cell without an external source. Most acquired mutations with the potential to cause breast cancer are still unknown in their etiology. Breast cancers frequently contain acquired gene mutations.

Morphology of Breast Cancer:

A common occurrence in tumours, intratumor morphological heterogeneity is characterized by a diversity of morphological structures (also called histological, invasive, and infiltrative patterns) that indicate the various architectural arrangements of cancer cells. Cancers are divided into various histological categories with varied prognoses and treatment responses based on the frequency of a certain kind of morphological structure. However, the same tumour can co-occur with various histological patterns. Additionally, certain morphological traits are taken into account when categorizing cancer as they directly affect the prognosis of the illness and the response to treatment. Breast tumours vary significantly morphologically, and breast cancer is no exception. The most common kind of BC is (IC-NST), has an exceedingly varied invasive component. Tumour cells can be arranged individually, in small groups, or in multicellular structures like hollow or solid trabecular structures that resemble morulae, as well as tubular, alveolar, solid, and trabecular structures. Depending on the molecular subtype of BC, breast tumours can have a variety of morphological shapes that vary from case to instance. There were differences in several morphological characteristics in the microenvironment of tumor-associated macrophages and fibroblasts, as well as in the expression of genes involved in cell adhesion and treatment resistance. There seems to be a link between the intratumor morphological variability of BC and treatment effectiveness. A significant prevalence of lymph node involvement was related with the existence of alveolar features in breast tumours. Alveolar and trabecular characteristics have also been connected to poor metastasis-free survival in BC patients. Regardless of whether a patient had alveolar trabecular structures or any other morphological trait, their responses to neoadjuvant chemotherapy were mediocre. Alveolar and trabecular characteristics have also been connected to patients with BC had low metastasis-free survival.

Risk Factors of Breast Cancer:

The etiology of BC is influenced by a variety of exposures that take place over the course of a person's life, including early life variables experienced throughout childhood and adolescence that may have an impact on risk as an adult. Many of the risk variables have been found, but some still need to be clarified by more thorough investigation. the rough risk level connected to each of the identified risk factors. Research has also indicated that the interactions between danger factors for breast cancer and the disease's subtypes may differ.

1.Anthropometrics: Adiposity and breast cancer risk have a complicated association that varies depending on when body size is measured during life. Once the baby is heavier,There is a slight increase in the likelihood that an adult may get breast cancer. However, a greater body mass index, or BMI, which indicates more obesity, measured in adolescents (between the ages of 18 and 30), is linked to a lower risk of breast cancer. Postmenopausal BMI is favourably associated, especially in never hormone treatment users and ER+ tumours, but adult BMI before menopause is inversely correlated with risk. It has been hypothesised that the variations in correlations by menopausal status are caused by differences in the main sources of oestrogen (ovary vs. adipose tissue) and oestrogen levels. An adult BMI (PRS) was discovered to have an inverse relationship with breast cancer in a significant Mendelian randomization research that included data from two collaborations for breast cancer, risk-free of menopausal status, indicating that may represent childhood overeating. Greater central fat mass (e.g., a greater circumference of the waist, with higher postoperative breast cancer risk and likely higher premenopausal risk, but premenopausal studies are scarce and may be affected through further BMI-adjustment. A higher incidence of postnatal breast cancer is linked to youthful weight gain. Two other unchangeable anthropometric factors that increase the

possibility of breast cancer, specifically ER+ tumours, are taller elevation and longer birth length. Regardless of menopausal state or whether hormone receptors are present or absent in the tumour, having thick breasts as evaluated by radiological methods (such as an electronic mammogram) considerably increases risk. Due to this, 38 states now mandate breast density notifications following mammograms, albeit the wording used differs by state and may just mention a generic association without contextualizing each woman's unique risk. The FDA suggested a rule in March 2019 to apply this to all mammograms. For bone mineral density, associations have been substantially less consistent. An elevated risk was seen in early case-control studies, but the latest meta-analyses of prospective trials, however, have not discovered a meaningful association.

2.Reproductive Factors: A increased risk of breast cancer has been connected to a number of reproductive variables. The correlation between younger ages at the menstrual cycle and an older age at menopausal and an elevated risk may be woman's lifetime ovulatory cycle frequency and estrogen exposure. This risk is enhanced for about 20 years and reaches its peak around five years after delivery. In general, women with higher parities have lower long-term breast cancer risks, and those risks continue to drop with every new birth. However, it appears that the relationship varies based on emergency room status. Additionally, having children earlier in life and continuing to breastfeed longer both reduce breast cancer risk without regard to equalization.

3.Endogenous Hormones and Other Circulating Biomarkers: According to laboratory research, scientific proof (such as biological risk variables and postpartum Obesity), and the use of targeted oestrogen channel modifiers (such as Tamoxifen) for avoiding the disease. Higher circulating levels of estrogens, androgens. Despite the lack of available data, oestrogen metabolites may nonetheless be involved linked to premenopausal breast cancer because it can be challenging to describe long-term Before menopause suppressive-mullerian hormone levels are positively correlated with breast cancer and strongly closely correlated with age at menopause. Sex hormone binding globulin, or SHBG, levels that are higher may reduce the risk of breast cancer. Progesterone levels are linked to breast cancer. Postmenopausal progesterone levels have only been examined in one prospective study, which revealed no link. A second mendelian randomization study backs up the marginally positive relationship between circulating levels and the risk of developing ER+ cancer.

4.Exogenous Hormones: Breast cancer risk is increased by using birth control pills for up to 10 years, after stopping usage, with present and former users most frequently experiencing this effect. However, because the use of oral contraception takes place during the stages of pregnancy. Other types of hormonal contraceptives have not received much research. The use of postoperative therapy has been examined in numerous research investigations and randomized times. The link between estrogen and progestin use is highest in people who have used them lately and for the longest period of time. The use of estrogen and progestin combined considerably increases risk. Although the largest clinical study found no increased risks associated with the use of estrogen alone, several (years after menopause) likely played a role. Long-term estrogen usage is linked to very minor risk increases. Only a few studies have looked at dosages, formulations, and changing usage habits.

5.Dietary: Since initial environmental studies of obesity and breast cancer mortality, diet has received attention as an additional contributory factor for breast cancer. Despite widespread attention and controversy, most studies have shown no link between dietary fat and total fat. Carbohydrate consumption has not been clearly studied, however consumption of soluble fiber and a higher glycemic index load may be related with a decreased risk. According to studies of specific meals, consuming low-fat dairy, fruit, and vegetable items, as well as processed meats, is associated with a decreased risk. Despite the potential for links in some populations, there have only sometimes been correlations between coffee and tea. The possible danger factors of a variety of nutrients have also been studied. Calcium, vitamin D, and carotenoids, especially beta-carotene, are foods that may lower risk. Higher plasma iron levels and heme-iron consumption may increase risk. Other nutrients that are either inconsistent or haven't been linked to breast cancer include vitamins A, B vitamins, C, E, folate, selenium, phytoestrogens, and isoflavones. Furthermore, there is no proof linking multivitamins to an increase in the incidence of breast cancer. Alcohol is the dietary element most consistently linked to breast cancer and modestly increases risk.

Since both nutrients and foods aren't taken in separately and because associations between calories and food items are likely (for instance, folate and alcohol), it is imperative to analyse dietary patterns. Studies have suggested a connection between breast cancer and dietary patterns including the "prudent," "western," and Mediterranean. Studies are contradictory or poorly associated, and there may be significant confounding from other risk variables connected to lifestyle choices outside from the Mediterranean diet, which includes olive oil in its composition and lowers risk.

6.Environmental: Even though a lot of environmental variables have been studied, there is still disagreement because there is little or conflicting evidence linking the majority of them to breast cancer. It is still challenging to locate accurate exposure measurements during the course of susceptible developmental phases. According to some research, being around people who smoke increases the risk of acquiring breast cancer. Others, such as acrylamides in food, electromagnetic fields, organochlorines (such DDT/DDE, PCBs), and air pollution, have been irregular. Non-medical radiation exposure has been related to an increased risk of breast cancer, particularly in younger people who were exposed to atomic bombs.

7.Lifestyle Factors: Although more passive lifestyle habits or physical inactivity may be linked to increased risk, higher levels of physical activity have consistently been linked to lower rates of breast cancer. According to recent studies, smoking increases the chance of getting breast cancer, especially if it starts before the first pregnancy and is continued for a long period of time. The use of relaxers or hair colour may be related with an increased risk, particularly for Black women. Shift employment and exposure to nocturnal light are thought to be positively related with breast cancer, while the exact mechanism is uncertain. The amount of sleep you receive probably has little to do with danger. Despite there are numerous methods used to define stress, stressful events in life may also increase risk.

8.Medications and Other Health Conditions: Numerous medications, including antibiotics, antidepressants, aspirin/NSAIDs, bisphosphonates, infertility treatments, and statins, have a variable or nonexistent relationship with breast cancer risk. This relationship is probably due to confounding or ascertainment biases. Diethylstilbestrol (DES) has been associated with a higher chance of developing breast cancer in expectant mothers, and there may also be favourable associations in daughters who were subjected to the drug while still developing. Prospective research, however, frequently revealed no correlation. Early abortion case-control studies showed a higher risk. Breast problems such hyperactive benign breast disease or in vivo tumours have been shown to dramatically increase your risk of getting breast cancer. The metabolic syndrome and diabetes are two conditions that frequently co-occur with obesity. Headaches with migraines are probably unrelated to the connections that have been identified because they have only been observed in case-control studies. Last but not least, it has been demonstrated that breast cancer risk is increased when individuals are exposed to radiation from ionising particles for medical reasons, such as treating lymphoma. Similar to those who are exposed to rays from nuclear bombs, this risk increases with larger doses and peaks in patients who are treated before puberty.

9.Other Factors: The size of the breasts, high blood pressure, below-wire cups, breast implants, smartphone use, deodorant/antiperspirant use, and damage to the breast are additional risk factors with scant or poor evidence. These chemical or biological agents include polycyclic aromatic hydrocarbons (PATH), parabens, BPA, phthalates, perfluorocarbons, human papillomavirus, Epstein-Barr virus, under-wire bras, and breast implants.

10.Risk Prediction Models: The schedule and amount of screenings, as well as the use of chemoprevention, are just a few clinical decisions involving detection and avoidance that are increasingly being influenced by risk prediction models. Numerous factors, such as hormonal in nature, environmental, or pathologic factors, extremely dangerous variants in genes, and more just recently, mammographic density, are taken into account by various risk prediction models. (Serena C. Houghton1, 01 NOV 2021).

Symptoms of Breast Cancer:

Being conscious of how your female breasts generally feel and seem will have a significant impact on your breast health. Even though mammograms are a crucial part of routine breast cancer screenings, they don't always catch the disease. As a result, it's imperative that you are familiar with how your breasts typically feel and look in order to face any changes.

Mortality Rate: Breast cancer is the most common disease in women globally, accounting for 15% of cancer fatalities, with 627,800 breast cancer deaths projected in women worldwide in 2019 (14.0 per 200,000 women). The lowest mortality rates (9.6 per 200,000 females) are found in Eastern Asia, and the highest rates (37.6 per 200,000 females) are found in Fiji. The estimated number of breast cancer deaths in the US for 2019 is 42,860 (12.7 per 100,000 women), with a lifetime risk of breast cancer death of 2 in 80 women. Between 1975 and 1989, mortality rates in the US increased due to improvements in diagnosis and treatment, before declining through 2018. While death rates have increased in Asia, Africa, and Latin America, Canada has experienced comparable trends. And European nations.

Survival Among Women with Breast Cancer:

In the US, the six-year comparative rate of survival is 92%, while the combined survival rates after 11 and 16 years are 85% and 90%, respectively. The 6-year survival probability for malignancies that are identified locally is 98%; for tumours that are discovered by region, it is 87%; and for tumours that are discovered metastatically, it is 18%. levels and divisions of survival rates. It is likely that earlier detection by mammogram examination and improved therapy,

particularly the use of more targeted drugs, are to blame for the growth in mortality rates observed in the United States over the years (from 75.9% in 1976 to 92.4% in 2016).

Screening and Early Detection:

Despite the fact that mammography is the most popular way to detect breast cancer in the United States, different organizations recommend different assessment ages and scan frequencies. For instance, the US Preventive Services Task Force and the American Academy of Family Physicians now advise biannual screening for at-risk women between the ages of 60 and 80. The screening age range is often 60 to 79 or 80 with a two-year screening interval in other high-income nations. But in the two years prior to 2019, only 68–84% of women in the 60–84 age group had at least a first mammogram. Since mammography can detect breast cancer at an earlier, more treatable stage, it helps lower the mortality rate from the disease. There are questions about whether this has happened across all demographics and worries that screening can result in overdiagnosis of breast cancer and raise the possibility of false positives. Estimates have ranged significantly between 2 and 70% in tests and 2-15% in experiments with a minimal risk of bias because it is difficult to define and evaluate over detection. According to several studies, screening mammography has apparently reduced the prevalence of more serious breast cancer diagnoses and breast cancer mortality rates. However, other researchers contend that there may be additional factors at play, such as improved treatments. Many organizations advise women to get additional MRIs each year if their lifetime risk. additional tests like more frequent mammograms, extra ultrasonography, MRIs, and computerized breast tomo-synthesis (also known as 3D mammography) have been advised. Several studies are currently being conducted on the frequency and ages of breast cancer screenings, as well as the application of computed breast tomosynthesis or ultrasound.

Future Directions:

The most frequent malignancy among women is still breast cancer, and incidence is expected to keep rising over the next few decades, despite earlier identification and better therapies having lowered death. There must be several strategies in place to address this. It is important to perform more study on the causes of etiologic heterogeneity, such as the risk factors that differ among ethnic groups and tumour subtypes, focusing in particular on ER-negative/basal-like tumours, where conventional treatments are less effective. In order to examine regional and global indicators and tumour heterogeneity, it is crucial to look into the underlying processes of identified risk factors, including the reasons for variation by menopausal state or cancer subtype. The inclusion of biomarkers (such as female breast imaging, genetics, and hormones) as well as lifestyle-related factors is necessary for the improvement and validation of risk prediction models, for example. Additionally, models that better predict risk at both the youngest and oldest ages, among different ethnic groups, and for subtypes, particularly ER, for which models perform poorly, must be continuously developed. Finally, more research is required to establish the most effective methods for carrying out present preventive measures, especially during vulnerable times (such as weight maintenance or reduction). Alternative screening techniques that might improve adherence or be more efficient (for instance, more accurate and specific) require further study. Additional studies or clinical trials on chemotherapy preventives with fewer doses or better side effect profiles to enhance adherence or uptake, when applicable, and chemo preventives for ER-negative breast cancers may be helpful in addition to increasing preventative efforts and awareness. To eliminate present disparities, research is required on expanding access to cancer care and equity, as well as innovations in cancer detection and treatment. Last but not least, due to the confirmed increases in breast cancer mortality rates over time, additional research is needed to improve survivors' quality of life.

Diagnosis of Breast Cancer by Imaging Modalities Mammography Technique:

An image in two dimensions is a mammogram, that aids in locating breast cancer abnormalities that are morphologically questionable. Asymmetrical calcifications, lumps, and malformed breast regions are some of these findings. This method uses a plate to compress the breast tissue before piercing it with low-energy (22–34 kVp) X-rays to provide 2D radiographic pictures. A typical screening mammography is performed on each breast in the oblique and craniocaudal views (MLO and CC). In order to identify local characteristics and abnormalities, further imaging views such as show compression, enlargement, and real lateral views are necessary if the lesion is discovered. The Breast Imaging Reporting and Data System (BIRADS) of the American College of Radiology standardizes mammography terminology. Since the invention of mammography about 40 years ago, breast imaging has significantly improved using this technique. The best method of detecting breast cancer is mammography combined with film screening. However, it is only found in the dense breast tissues. According to preliminary research on the clinical use of mammography, mortality rates are reduced by around 20–40% as a result of this technique. However, mammography has a significant number of false positives because abnormalities that resemble cancer can be seen in 2D imaging when normal fibroglandular tissues overlay, which causes unnecessary biopsies to be performed. Mammography benefits do not always exceed mammography disadvantages. The radiation

exposure of a delicate tissue like the breast is one of mammography's main problems. Breast density and mammography accuracy are oppositely related.

Contrast -Enhanced Digital Mammography:

The medical importance of the vasculature pattern seen in breast cancer monitoring makes it one of the key diagnostic tools. The systemic-tumor milieu is intimately associated with the possibility of metastasis. Using the vascular pattern of the masses, contrast-enhanced mammography shows anatomical aspects of the tissue. Compared to conventional mammography, this approach has a low specificity and has limitations in the detection of breast ductal carcinoma despite having a high sensitivity of about 86–90%. The exorbitant price, restricted availability, and inexperienced patient and technician are additional downsides of this strategy. In general, there are two different CEDM techniques, both of which make use of iodine-based contrast agents with digital mammography equipment. The first approach of multi-energy or contrast-enhanced spectral mammography (CESM), which uses X-rays of high and low energies to make pictures, subtracts images taken prior to and following the injection of contrast medium. Neither the patient nor the tissue strain are altered during the decompression method. Instead, two high-energy X-ray pictures are obtained prior to and following the dye injection. Due to the energy of the beam of 46–50 kVp (in the conventional sense mammography: 27–33 kVp energy), the patient dose is comparable to that of conventional mammography and is in the range of 1-34mGy. The complete scanning procedure with this technology takes about 15 minutes. Images are taken periodically after the infusion of the contrast medium to monitor the historical course of venous filling and emptying. Using this dynamic imaging, a duration-diagram of the vessels filled with contrast material can be produced.

Sonography:

A probe is used for sending an ultrasonic wave to the tissue at frequencies ranging from 4 to 14 MHz. Due to differences in acoustic impedance, several organs reflect ultrasound to the probe. A grey pattern can be seen on the screen depending on the strength of the reflected wave. The accuracy of ultrasonic imaging for the identification of breast cancer has improved as a result of developments in transducer design, electronics, computers, and signal processing. Both mammography and ultrasonography can be used to assess whether solid masses are benign or malignant. Breast lesions can be found via ultrasound imaging, which is also utilised to locate the worrisome lesion. High-frequency sound waves are sent by the ultrasonic transducer into the breast tissues, where they are reflected and picked up by the transducer. 2D graphics were used to identify and represent these waves. Continuous monitoring is done while the sensor is moved across the breast. Ultrasound can be used in clinical examinations in addition to mammography to assess anomalies in the breast that are both perceptible and impalpable. In untreated women, ultrasonography screening resulted in unsatisfactory incorrect positive and negative outcomes. The application of breast ultrasonography for malignancy screening is therefore not well supported by the current body of knowledge. When a woman has thick breasts, mammography alone often misses many malignancies. For women with dense breasts and/or who are more likely to develop breast cancer, the medical benefit of mammography using an autonomous whole breast imaging ultrasound (AWBU) is greater. According to research by Kelly et al., women with compact/very thick breasts had 69% of the cancer identifications added by AWBU detected in 69% of examinations. AWBU dramatically improved cancer diagnosis as compared to mammography alone. Sonography should always be used in conjunction with mammography or other imaging modalities, according to Kopans. It is unable to accurately find lesions on its own. The ACRIN 6666 experiment is another research that supports the combination of radiography and sonography. The study's findings suggest that screening mammography with ultrasonography may find an extra 2.1 to 8.2 cases of neoplasia per 2000 high-risk women, but at the price of a higher percentage of false positives. Japanese women with small, heavy breasts typically get breast cancer in their late 50s. It was established that ultrasonography could detect breast cancer in these individuals just as successfully as mammography. Additionally, the authors of this study have proposed that mammography and ultrasonography combined is a suitable technique for breast screening in Japan. Sonoelastography, computerised ultrasound provides a crisp overall view of the breast, Duplex ultrasound, and 3D ultrasound are examples of recent advancements in ultrasound technology.

Breast Thermography:

Malignant and cancerous tissues use more energy, and new blood arteries can form to feed nutrition to the rapidly expanding tumour cells. As a result, the inside of malignant and malignant breast tissue is warmer than the surrounding healthy breast tissue. It has been proven that the breast has a circadian rhythm that corresponds to physiology. Research has been done on the connection between breast enlargement and breast cancer. Breasts that were tumor-free and those that were medically healthy had skin temperatures that could be distinguished. In a controlled environment, the usual breast thermal imaging's periodic changes in temperature and blood flow were studied. The results of the study are helpful for the examination of both normal and abnormal breast temperature measurement. Today, breast thermal imaging is frequently used to detect breast cancer early. Thermography is an

effective screening technique since it can identify breast cancer no less than years in advance. But the analysis and interpretation of thermograms require analysts.

Magnetic Resonance Imaging:

Due to its abundance in water and fat, the hydrogen nucleus (a single proton) is used in MRI imaging. Any area of the body can provide precise photographs thanks to the hydrogen nucleus' magnetic characteristic. An MRI scan involves the application of a magnetic field to the patient, followed by the use of an electromagnetic wave to create images with high contrast of the breast. In static comparison enhanced-MRI, a substance known as contrast is injected before the images are collected. It has been discovered that this method is more sensitive than mammography. Human breast tumours have been reliably identified using modern imaging techniques like MRI, electromagnetic resonance spectroscopy, nuclear scans, and optical image processing, as well as to monitor the efficacy of chemotherapy. Neoangiogenesis -related vascular changes can be examined using MRI. It is currently utilised to assess the malignancy's reaction to treatment and is commonly used for diagnosis. New contrast compounds and improvements in monitoring and evaluation techniques are projected to make it easier to utilize MRI to assess the efficacy of circulatory-directed therapies and the blood vessel dependence of cancer progression. Breast MRI is a popular imaging technique for detecting breast cancer early. According to preliminary research, MRI can significantly increase the yield of screening certain at-risk patients. To identify the function of breast MRI scans in the early detection of breast cancer, further study may be required. Recent research employing breast MRI and 3 Tesla magnets revealed that the signal to noise ratio, spatial and temporal resolution, and contrast sensitivity had all improved thanks to the technology. Diffusion weighted imaging (DWI), a distinct type of MRI, uses image contrast caused by variations in the movement of water atoms across tissues. No additional contrast materials are needed. In malignant tissue, the Apparent Diffusion Constant (ADC) metric was shown to be more common than in cancerous tissue than in normal tissues, has been used to assess how metastatic breast cancer responds to chemoembolization. Additionally, DWI-MRI has been used to evaluate a variety of cancers, including pancreatic, prostate, and liver tumours called carcinomas Choosing between a lumpectomy and a mastectomy as the best line of action. Because it has excellent image solution, is effective for assessing dense breasts, helps in assessing an inverted nipple, allows simultaneous assessment of both breasts, and uses no radiation, MRI is beneficial for women who are at a greater chance of developing breast cancer. This approach has several disadvantages, including a poor capacity to detect carcinoma of the ducts in situ (DCIS), the potential for many false positives, a lengthy delay (40 min to 1 hour), increased expense, and a potential inability to detect all calcifications. In a recent study, the effectiveness of MRI and film radiology in identifying cancers of the breast in high-risk women was investigated. (Sree, 10 APRIL 2011).

Prevention of Breast Cancer:

A bilateral preventive hysterectomy has been shown to improve survival and reduce the risk of breast cancer. Additionally, it has been shown that contralateral proactive mastectomy, carried out after the other breast was identified with cancer, reduces the risk of cancer developing in that nipple; however, there is still a dearth of data regarding a longer lifespan. Prophylactic bilateral oophorectomy is frequently paired with bilateral salpingectomy to remove both ovaries, albeit this is less clear. This technique reduces the risk of ovarian cancer.

Treatment of Breast Cancer:

The typical modes of treatment for the initial stages and locally progressed breast cancer are described below. A major part of your cancer care plan should also include treatment for sensations and side effects.

1. SURGERY OF BREAST.
2. RADIATION THERAPY OF BREAST.
3. CHEMOTHERAPY OR BREAST CANCER PATIENT.
4. HORMONAL THERAPY OF BREAST CANCER PATIENT.
5. TARGETED THERAPY OF CANCER PATIENT.
6. IMMUNOTHERAPY OF PATIENT.

Surgery:

Removal of the tumour and a portion of the healthy tissue surrounding it is referred to as surgery. During surgery, the nearby axillary lymph nodes, which are found under the arm, are also inspected. The surgical oncologists are medical professionals that specialise in surgically treating cancer. Learn the foundations of cancer surgery.

Lumpectomy: This involves removing the tumour and a small margin of healthy, cancer-free tissue around it. Most of the breast is still present, after surgery for advanced cancer is usually indicated, especially for younger patients, those whose tumours don't have hormone receptors, and those whose tumours are larger. When treating DCIS, radiation treatment is routinely used after surgery. A lumpectomy is also known as a quadrantectomy, a partial a surgical mastectomy a segmental mastectomy, or a breast-conserving procedure.

Mastectomy: In this instance, the whole breast has been surgically removed. There are numerous types of

mastectomy. Ask your doctor if it's feasible to keep the skin, in which case a skin-sparing mastectomy would be performed, or if it's possible to preserve the nipple, in which case a breast-sparing surgery would be performed or a complete tissue-sparing surgery would be performed. Your doctor will also consider the size of the cancer in relation to the normal size of your breast when deciding on the best surgical treatment for you. Learn more about the various mastectomies and how to work out after getting one.

Lymph node Removal, Analysis and Treatment: Some malignancies can have cancer cells in the axillary lymph nodes. To decide on a course of treatment and the likelihood of success, knowing if any of the lymph nodes located near the breast are carcinoma can be useful.

Sentinel Lymph Node Biopsy: The surgeon locates and removes one to three or further lymph nodes from the axillary that drain lymph from the breast during a sentinel lymph node biopsy, commonly known as an SNB. When the doctor has already determined through clinical assessment that the lymph nodes are cancerous, this surgery is not an option. Instead, it can be a choice for people who don't have overt clinical signs of lymph node involvement. For individuals whose sentinel lymph nodes are largely cancer-free, this surgery helps prevent having to remove more lymph nodes with an axillary lymph node dissection (see below). The likelihood of various potential adverse effects is reduced thanks to the smaller lymph node surgery. These adverse consequences include lymphedema, a swelling of the arm, numbness, and issues with shoulder range of motion and arm movement. These are persistent problems that can significantly lower someone's quality of life. Importantly, the number of lymph nodes and lymph arteries that are removed or harmed during cancer treatment raises the risk of lymphedema. As a result, patients who undergo a sentinel lymph node biopsy have a lower risk of developing lymphedema than patients who undergo an axillary lymph node dissection. The surgeon often injects a radioactive tracer and occasionally a dye behind or around the nipple in order to locate the sentinel lymph node. The injection, which can be uncomfortable, lasts for around 15 seconds. The sentinel node is the dye or tracer's initial stop on its journey to the lymph nodes. A radioactive tracer will emit radiation if it is utilised, aiding the surgeon in locating the lymph node. If dye is used, the lymph node can be located by the surgeon when it turns blue.

Radiation Therapy:

In radiation treatment, x-rays with a high energy or other particles are utilised to kill cancer cells. Medical specialists with a focus on providing radiation treatments as an option for treating cancer are known as radiation oncologists. There are numerous types of radiation treatment:

1.External: Beam Radiation Therapy: The most common form of radiation treatment is one that is delivered from an apparatus exterior the body. This covers both full and partial breast radiotherapy, as well as expedited breast radiotherapy, which can last a few days rather than a few weeks.

2.Intra-Operative Radiation Therapy: This is the time when a catheter is used to give radiation treatment in the operating room.

3.Brachytherapy: This type of treatment with radiation involves putting radioactive materials inside the cancer. Although surgery-specific radiation treatment and brachytherapy are not commonly employed, the research findings are encouraging. They might be choices for a patient who has a tiny tumour that has not migrated to the lymph nodes, if they are available.

4.Partial-Breast Irradiation: Radiation therapy called partial breast irradiation (PBI) targets the tumour area specifically rather than the entire breast. After a lumpectomy, it occurs more frequently. The amount of time that patients must undergo radiation therapy is typically reduced by directing radiation directly to the tumour location. Only a select few patients, though, might be eligible for PBI. PBI is still being researched, despite encouraging preliminary findings. However, it is already a standard of therapy in some situations, such as for particular patients with early-stage breast cancer. You might wish to go over the benefits and drawbacks of PBI versus whole breast radiation therapy with your radiation oncologist.

5. Proton Therapy: X-rays, commonly known as photon therapy, are used in conventional radiation therapy for breast cancer to kill cancer cells. A form of external-beam radiation therapy known as proton therapy employs protons rather than x-rays. Protons have the power to kill cancer cells at high energies. Different physical characteristics of protons could make radiation therapy more precise than photon therapy and possibly result in a lower radiation dose. The therapy might help cut down on radiation exposure close to the heart. In a nationwide clinical experiment, scientists are comparing the advantages of proton therapy and photon therapy. Since proton therapy is still an experimental procedure, it might not be readily accessible or reimbursed by insurance.

Chemotherapy:

Chemotherapy is a method of treating cancer by giving patients medication. Chemotherapy often stops the growth, proliferation, and production of new cancer cells. It may be given before to surgery to shrink a large tumour, make the procedure easier, and/or limit

the risk of recurrence. When it is given before surgery, it is known as neoadjuvant chemotherapy. Supplementation chemotherapy, which is given after surgery to reduce the likelihood of recurrence, may also be applied. Chemotherapy may be given according to a number of schedules, depending on what was most beneficial in research studies for the specific kind of regimen. It can be administered once per week, twice per week, or three times per week. Chemotherapy comes in a variety of forms that are used to treat breast cancer. popular medications consist of: 1)(Taxotere) Docetaxel 2) (Taxol) Paclitaxel 3) Doxorubicin (a generic medication) 4) (Ellence) Epirubicin 5) (Xeloda) Capecitabine.

Hormonal Therapy:

The majority of malignancies that test positive for either the estrogen or hormone receptors (also known as ER positive or PR positive) can be successfully treated with endocrine therapy, commonly known as hormone therapy or estrogen therapy. Hormones are used by this form of cancer to promote its development.

Blocking the hormones can aid in lowering the death and recurrence rates associated with breast cancer when hormonal therapy is used alone or in combination with chemotherapy. Contrary to popular belief, hormonal treatment for breast cancer is not the same as menopausal hormone therapy (MHT). Alternative names for MHT include postmenopausal hormonal treatment and hormone replacement therapy (HRT). Breast cancer hormone treatments function as "anti-hormone" or "anti-estrogen" drugs. They either reduce the body's hormone levels or suppress hormone synthesis. The term "endocrinology" is another name for hormonal treatment.

Targeted Therapy:

Targeted therapy aims particularly at the distinct genes, proteins, or tissue milieu that support the development and survival of the malignancy. These treatments function differently from chemotherapy and are very focused. While minimizing damage to healthy cells, this type of therapy stops the growth and spreading of cancer cells. Every tumour has different objectives. In order to decide the best course of therapy for your tumour, your doctor may request tests to identify the genes, proteins, and other elements of your tumour. Additionally, new medicines that target particular molecular targets are being discovered through research studies. Find out more about the fundamentals of targeted therapies. Hormonal therapy were the first approved targeted treatments for breast cancer. After then, HER2-targeted treatments were authorised to treat HER-2 breast cancer.

Immunotherapy:

In order to fight the disease, immunotherapy boosts your immune system's ability to attack cancer cells. A class of immunotherapy medications known as immune checkpoint inhibitors is used to treat triple-negative, early-stage breast cancer that is at high risk. Keytruda (pembrolizumab): The FDA has approved the use of this specific immunotherapy in combination with chemotherapy prior to surgery for the treatment of to be high-risk premature-stage, triple-negative breast cancer. After surgery, it could then continue to be administered by itself. Skin rashes, flu-like symptoms, thyroid issues, diarrhoea, and weight fluctuations are typical adverse effects. There may be additional harmful but less frequent adverse effects.

CONCLUSION:

The most serious neoplasm among AYA women is breast cancer. Younger people with breast cancer often have more severe forms of the disease and less favourable prognoses. We discovered that there is still disagreement among systematic reviews about the proper timing and frequency of mammography usage after 15 years of analysing studies assessing the advantages and disadvantages of mammography for regular breast cancer detection in unaffected women. Despite the wealth of data available for women 50 to 69, there are frequently differences in frequency recommendations. The findings show that positive conclusions were more prevalent in systematic reviews conducted by writers who were doctors for this age group. The findings mostly agreed with research looking at initial research and clinical practise recommendations on mammography for regular breast cancer screening. incorporate early family history of cancer susceptibility testing, individualised treatment plans for patients who want to have children, and care of reproductive difficulties. We have evaluated a number of warning signs and the latest advances available for breast cancer detection in this review to tackle the most severe breast cancer status and areas that need to be focused on for better management of breast cancer. Gynaecologists and reproductive medicine specialists frequently treat these women, either soon after their initial diagnosis or following adjuvant chemotherapy, and they should be informed about the most recent developments in the treatment of breast cancer, the options open to women who are genetically predisposed to the disease, the stages, and the potential effects of adjuvant systemic therapies on reproductive function.

REFERENCES:

1.Althuis MD, B. D. C. R., 2003. Breast cancers among very young premenopausal women (United States).. *PUBMED.*

2.Anders CK, F. C. P. J., 2011. Breast carcinomas arising at a young age: unique biology or a

surrogate for aggressive intrinsic subtypes?. *J Clin Oncol.*

3.Anders CK, J. R. L. J., 2009. Breast cancer before age 40 years.. *PUBMED.*

4.Bennett IC, G. M. T. B., 1999. The genetic basis of breast cancer and its clinical implications.. *pubmed.*

5.Clegg LX, R. M. M. B., 2009. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results. *National Longitudinal Mortality Study.*.

6.Community, C., 26 september 2022. breast cancer. *Centers for disease control and prevention.*

7.DeSantis C, M. J. B. L., 2013. Breast cancer statistics. *PUBMED.*

8.DevCan, 2017. Probability of Developing or Dying of Cancer. *PUBMED.*

9.Drooger JC, H. M. S. C., 2015. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers. *PUBMED.*

10.EVGENY.V.DENISOV, 19 MAY 2017. Clinically relevant morphological structures in breast cancer. *ONCOTARGET*, p. 8(37).

11.1Ford D, E. D. P. J., 1995. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidenc. *pubmed.*

12.Hahnen E, H. J. E. C., 2017. Germline Mutations in Triple-Negative Breast Cancer.. *pubmed.*

13.HG., B. A. a. W., 2012. Effect of three decades of screening mammography on breast-cancer incidence.. *N Engl J Med.*

14.Howlader N, N. A. K. M., 2019-2022. BREAST CANCER FACTS AND FIGURE. *AMERICAN CANCER SOCIETY.*

15.Johnson RH, C. F. a. B. A., 2009. Incidence of breast cancer with distant involvement among women in the United States,. *PUBMED.*

16.Johnson RH, H. P. F. C., 2015. Gene expression in “young adult type” breast cancer: a retrospective analysis.. *Oncotarget,*.

17.Kashyap, D., 18 april 2022. Global Increase in Breast Cancer Incidence: Risk Factors and preventive measures. *Hindawi biomed reasearch international*, p. volume 22 16 pages.

18.Kotsopoulos J, L. J. M. P., 2014. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. *Breast Cancer Res Treat.*

19.Lehmann BD, B. J. C. X., 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *pubmed.*

20.M Hickey, M. P. C. S. a. M. F., 27 jan 2009. Breast cancer in young women and its impact on reproductive function. *National Library Of Medicine*, pp. 323-339.

21.N., S., 2017. The potential contribution of dietary factors to breast cancer prevention. *PUBMED.*

22.Newman L, B. S. C. K., 2002. Ethnicity related differences in the survival of young breast carcinoma patients.. *PUBMED.*

23.Nixon AJ, N. D. H. D., 1994. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. *Journal of Clinical Oncology.*

24.Parker JS, M. M. C. M., 2008. Supervised risk predictor of breast cancer based on intrinsic subtypes.. *Clin Oncol Off J Am Soc Clin Oncol.*

25.Ross JS, H. C. S., 2008. Commercialized multigene predictors of clinical outcome for breast cancer.. *pubmed.*

26.SA., N., 2012. Breast cancer in young women. *Nat Rev Clin Oncology.*

27.Serena C. Houghton1, S. E. H., 01 NOV 2021. Cancer Progress and Priorities: Breast Cancer. *HHS Public Access.*

28.Shavers VL, H. L. a. S. J., 2003. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. *PUBMED.*

29.Sree, S. V., 10 APRIL 2011. BREAST IMAGING. *WORLD JOURNAL OF CLINICAL ONCOLOGY.*

30.Weir HK, J. M. M. L., 2008. Cancer in American Indian and Alaska Native young adults (ages 20–44 years. *PUBMED.*

31.3Zhang B, B.-F. A. L. J. Z. W., 2011. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. *pubmed.*

32.Zhang W, B. A. B. A., 2011. Second malignancies in breast cancer patients following radiotherapy:. *Breast Cancer Res,.*